Literature DB >> 12891543

Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine.

Tor C Savidge1, Wei-Hua Pan, Paul Newman, Michael O'brien, Pauline M Anton, Charalabos Pothoulakis.   

Abstract

BACKGROUND & AIMS: Clostridium difficile causes antibiotic-associated diarrhea and pseudomembranous colitis, diseases afflicting millions of people each year. Although C. difficile releases 2 structurally similar exotoxins, toxin A and toxin B, animal experiments suggest that only toxin A mediates diarrhea and enterocolitis. However, toxin A-negative/toxin B-positive strains of C. difficile recently were isolated from patients with antibiotic-associated diarrhea and colitis, indicating that toxin B also may be pathogenic in humans.
METHODS: Here we used subcutaneously transplanted human intestinal xenografts in immunodeficient mice to generate a chimeric animal model for C. difficile toxin-induced pathology of human intestine.
RESULTS: We found that intraluminal toxin B, like equivalent concentrations of toxin A, induced intestinal epithelial cell damage, increased mucosal permeability, stimulated interleukin (IL)-8 synthesis, and caused an acute inflammatory response characterized by neutrophil recruitment and tissue damage. Laser capture microdissection and real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) showed that intestinal epithelial cell-specific IL-8 gene expression also was increased significantly after luminal exposure to C. difficile toxins in vivo.
CONCLUSIONS: We conclude that C. difficile toxin B, like toxin A, is a potent inflammatory enterotoxin for human intestine. Future therapeutic or vaccine strategies for C. difficile infection therefore need to target both toxins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12891543     DOI: 10.1016/s0016-5085(03)00902-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  96 in total

Review 1.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

2.  Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

Authors:  Jennifer Steele; Kevin Chen; Xingmin Sun; Yongrong Zhang; Haiying Wang; Saul Tzipori; Hanping Feng
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

3.  Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.

Authors:  Rory N Pruitt; Nicole M Chumbler; Stacey A Rutherford; Melissa A Farrow; David B Friedman; Ben Spiller; D Borden Lacy
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 4.  Clostridium difficile toxins: mechanism of action and role in disease.

Authors:  Daniel E Voth; Jimmy D Ballard
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  Application of mutated Clostridium difficile toxin A for determination of glucosyltransferase-dependent effects.

Authors:  Matthias Teichert; Helma Tatge; Janett Schoentaube; Ingo Just; Ralf Gerhard
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

6.  Clostridium sordellii lethal toxin kills mice by inducing a major increase in lung vascular permeability.

Authors:  Blandine Geny; Huot Khun; Catherine Fitting; Leticia Zarantonelli; Christelle Mazuet; Nadège Cayet; Marek Szatanik; Marie-Christine Prevost; Jean-Marc Cavaillon; Michel Huerre; Michel R Popoff
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

7.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

8.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

Review 9.  Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.

Authors:  Milena M Awad; Priscilla A Johanesen; Glen P Carter; Edward Rose; Dena Lyras
Journal:  Gut Microbes       Date:  2014

10.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.